Characterization and in vitro cytotoxic effect of adriamycin conjugated monoclonal antibody prepared against breast cancer cell line

Hisanori Ikegaki, Noriaki Ohuchi, Takashi Masuko, Shinya Suzuki, Yuko Harada, Susumu Satomi, Yoshiyuki Hashimoto

Research output: Contribution to journalArticle

Abstract

We have produced an adriamycin-conjugated monoclonal antibody, AM1, covalently linked by acid-labile cis-aconitic spacer. The immunoconjugate, cisaconitic adriamycin (cAA)-AM1, was confirmed to retain the binding activity against human breast cancer cell lines by flow cytometry. The immunoconjugate was shown to be internalized into antigen-positive cancer cells by flow cytometry analysis and high performance liquid chromatography. Antitumor effects of cAA-AM1 were assessed on human breast cancer and colon cancer cell lines, with inhibition of 3H-leucine uptakes to the cells, c A A-AM1 demonstrated a selective cytotoxicity to ZR-75-1 which was reactive with AM1, whereas it showed no antitumor effect on SW1116 cells which did not react with AM1. Free adriamycin demonstrated a nonselective cytotoxicity against both cell lines. AM1 alone and cAA-control IgM did not show any antitumor effect on ZR-75-1. These results suggest that cAA-AM1 retains binding activity and specificity against breast cancer cells in vitro.

Original languageEnglish
Pages (from-to)85-92
Number of pages8
JournalBreast Cancer
Volume4
Issue number2
DOIs
Publication statusPublished - 1997 Jul 1

Keywords

  • Adriamycin
  • Breast cancer
  • Immunoconjugate
  • Monoclonal antibody
  • Targeting therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Characterization and in vitro cytotoxic effect of adriamycin conjugated monoclonal antibody prepared against breast cancer cell line'. Together they form a unique fingerprint.

  • Cite this